Inhibikase Therapeutics, Inc. (IKT)

Market Cap	11.98M
Revenue (ttm)	260,501
Net Income (ttm)	-19.03M
Shares Out	6.48M
EPS (ttm)	-3.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,588
Open	1.820
Previous Close	1.870
Day's Range	1.712 - 1.820
52-Week Range	0.790 - 4.350
Beta	1.20
Analysts	Strong Buy
Price Target	27.00 (+1,383.52%)
Earnings Date	May 13, 2024

About IKT

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development coll...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 23, 2020
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: IKT

Financial Performance

In 2023, IKT's revenue was $260,501, an increase of 111.03% compared to the previous year's $123,440. Losses were -$19.03 million, 5.40% more than in 2022.

Analyst Forecast

According to one analyst, the rating for IKT stock is "Strong Buy" and the 12-month stock price forecast is $27.0.

Price Target

$27.0

(1,383.52% upside)

Analyst Consensus: Strong Buy